Kamada Announces Two-Year Extension of KEDRAB® Distribution Agreement with Kedrion in the U.S.

Kamada Ltd. has announced that Kedrion, a leading biopharmaceutical company, has exercised its option to extend the distribution agreement for KEDRAB® in the United States. This extended agreement will be in effect until March 2026. Additionally, both companies are currently engaged in discussions regarding further expansion of their collaboration. In the year 2022, Kamada generated approximatel..